When the curtain goes up at ASCO here tomorrow, you can bet that one subject will dominate the entire conference: immuno-oncology. But the number of prominent players on the immunopalooza stage this year is likely to grow as analysts fix on the swelling lineup of studies that are attracting global attention from cancer patients and physicians.

…read more

Source: ASCO: Big Four immuno-oncology players wager $1.3B on next-gen cancer drugs


0 No comments